As per Future Market Insights’ latest industry analysis, the valuation for the global clot busting drugs market is estimated to be around USD 28.8 Billion in 2022 and is projected to exhibit a CAGR ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares ...

The IN route potentially improves systemic bioavailability of drugs since it bypasses gastrointestinal ... hydrochloride (HCl), and the effect of an oral decongestant (pseudoephedrine) or nasal ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

In North America, particularly the United States, innovation in menopause care and a modern healthcare infrastructure provide a strong foundation for steady growth at a 3.00% CAGR through 2034. Canada ...

A traveller’s persistent diarrhoea uncovers a surprising dual infection. Explore why detailed history and diagnostics are ...

In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Attendees will hear from local historians and community leaders and witness the ceremonial passing of the axe, symbolizing the start of the relay hike. There will also be a Daniel Boone reenactor on ...

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging ... that will provide additional cash for its main drug candidate – oral CETP inhibitor obicetrapib.